[Effectiveness of metabolic therapy in elderly patients with discirculatory encephalopathy and moderate cognitive disorders.]

The effectiveness of neurometabolic therapy in patients with various stages of discirculatory encephalopathy was assessed according to the severity of cognitive impairment. Using a number of studies [clock drawing test, MMSE, Spielberger-Hanin, Bourdon test and cognitive evoked potentials (P300 peak)], cognitive functions of 60 elderly patients (mean age - 61,3±12,4 years) with various degrees of chronic head ischemia were analyzed brain and discirculatory encephalopathy of the I-III stages. Depending on the treatment regimen, patients were divided into 2 groups: 34 (the main group) received Cytoflavin in the treatment regimen: 2 tablets 2 times/day for 2 months. The comparison group consisted of 26 patients who received basic therapy without Cytoflavin. The majority (81,7%) of patients revealed cognitive disorders of varying severity. The inclusion of Cytoflavin in the treatment regimen improved the performance of neuropsychological tests (concentration and stability of attention, memory indicators, decreased reactive anxiety and smoothing signs of dementia), as evidenced by the positive dynamics of the CVP test (shortening the latency period and increasing the amplitude of the P300 peak, and as a result, reducing the coefficient latency / amplitude ratios).

[Event-related potentials in moderate cognitive impairment in patients with chronic cerebral ischemia treated with cytoflavin].

Authors compared cognitive functions in 60 patients (main group) with different stages of discirculatory encephalopathy (DE), I, II and III stages. A comparison group included 10 age-matched normals without DE. All patients underwent a clinical-neurological investigation and performed neuropsychological tests (MMSE, the Clock drawing test, Burdon probe) and Spilberger-Khanin test. Cognitive evoked potentials, including P300, were recorded. Results revealed the decrease in performance on neuropsychological tests and P300 components that indicated the slowing of metabolic processes in the cerebral cells of patients with DE. In patients treated with cytoflavin, the activation of metabolic processes in the brain cells that indicated the protection of the cellular cluster clinically manifested itself in neurocognitive and electrophysiological improvements was observed.